

Neuro-Halakha

Exploratory research into adapting interfaces to user rhythms and signals.

Exploratory concept · Filing not verified

Buyer need

Chronobiology and EEG laboratories may explore voluntary, non-clinical uses.

Available evidence

The concept is described in the portfolio; no human validation was observed.

What remains to be demonstrated

Feasibility, safety and an independent evaluation protocol.

Neuro-Halakha

Market and alternatives

Chronotype and cognition have been studied. Emotiv provides EEG hardware and development tools.

Potential buyers


Human–computer interaction laboratories

Next fundable milestone

Assess scientific relevance and the constraints of an initial study.

Decision criterion

Proceed with scientific assessment. Do not make health-benefit claims.



Targeted, non-exhaustive research. Commercial conclusions are hypotheses. These sources establish no acquisition interest in DreamNova.

Validation budget

Neuro-Halakha

\$5,701 – \$17,105

30 to 60 days, initial feasibility

Planning assumptions, not quotations or valuations. The bounds are two spending scenarios, not a statistical confidence interval. Further investment depends on milestone results.

Engineering

Low scenario	\$3,421
High scenario	\$10,263

Computing, hardware or external laboratory

Low scenario	\$1,425
High scenario	\$4,276

Preliminary IP review

Low scenario	\$855
High scenario	\$2,566

Planning assumption, not a quotation or an asset valuation. Includes preliminary IP review; excludes drafting and filing, a full freedom-to-operate assessment, tax, industrialisation and regulatory studies. Deduct any services that overlap with a future filing quotation.

Public sources

[Chronotype and cognition — 2021 study.](#)

[Emotiv — EEG developer tools](#)

Planning amounts are expressed in US dollars using the ECB reference rates dated 25 September 2026. These are indicative conversions, not bank transaction rates or supplier quotations.

Contact · admin@holyrentals.com